Alnylam Pharmaceuticals (ALNY) Cash & Equivalents (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has 18 years of Cash & Equivalents data on file, last reported at $1.7 billion in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 67.78% year-over-year to $1.7 billion; the trailing twelve-month figure through Mar 2026 stood at $1.7 billion (up 67.78% YoY), and the FY2025 full-year result was $1.7 billion, up 71.09% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $1.7 billion, up from $1.7 billion in the prior quarter.
• Across five years, Cash & Equivalents topped out at $1.7 billion in Q1 2026 and bottomed at $534.1 million in Q1 2022.
• The 5-year median for Cash & Equivalents is $968.7 million (2024), against an average of $996.3 million.
• The widest annual swing landed in 2022, when Cash & Equivalents dropped 22.82%; it then jumped 71.09% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $868.6 million in 2022, then decreased by 6.43% to $812.7 million in 2023, then grew by 19.19% to $968.7 million in 2024, then surged by 71.09% to $1.7 billion in 2025, then advanced by 3.23% to $1.7 billion in 2026.
• The last three Cash & Equivalents figures came in at $1.7 billion (Q1 2026), $1.7 billion (Q4 2025), and $1.5 billion (Q3 2025), per Business Quant data.

Peer Comparison